Asia
Biotech and pharma companies strengthen their leadership teams with these appointments. Who made power moves in the industry this past week?
ADNEC and Abu Dhabi Convention Bureau collaborate to attract key conferences to the capital
he Ministry of Health and Prevention recently met with a Chinese delegation to discuss mutually beneficial cooperation in the use of technological innovations such as artificial intelligence (AI) in the health care sector.
Following the recent claims by He Jiankui, a scientist and professor of Biology at the Southern University of Science and Technology in Shenzhen, Guangdong, China, that he has successfully created the world’s first gene-edited babies,
Todos Medical Ltd. announced that it has entered into a Joint Venture Agreement (JV Agreement) with biotechnology holding company Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) to develop LymPro Test® as a diagnostic blood test for Alzheimer’s disease.
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
Although it was probably not in serious peril, shareholders of Japan’s Takeda Pharmaceutical voted to approve the acquisition of Dublin’s Shire. The deal is currently valued at $58 billion.
Seattle Genetics and Takeda show off the impressive survival data that prompted the FDA to give approval to Adcetris for this indication.
At least one U.S. researcher who was in touch with He Jiankui and his team speculates that the second pregnancy may involve a baby or babies whose PCSK9 gene was editing using CRISPR. PCSK9 is involved in control of cholesterol.
A*STAR’s Institute of Microelectronics (IME) and One BioMed, an A*STAR spin-off, launched a S$9 million joint lab on Thursday (29 November).
PRESS RELEASES